首页> 外文期刊>Oncology reports >Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance
【24h】

Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance

机译:microRNA在顺铂耐药卵巢癌细胞中的表达改变和与MDR1 / P-糖蛋白介导的耐药相关的miR-130a上调

获取原文
获取原文并翻译 | 示例
           

摘要

microRNAs (miRNAs) are short non-coding RNA molecules which are involved in the regulation of various biological processes. Drug resistance has become a major obstacle to successful chemotherapy of ovarian cancer. The aim of this study was to investigate microRNA expression profiles in cisplatin-resistant ovarian cancer cells and the role of miR-130a in regulating drug resistance. Analysis of differentially expressed miRNAs between SKOV3 and SKOV3/CIS cells was assessed by miRNA microarrays. Target prediction of miRNAs was determined with the help of PicTar or TargetScan. Among these miRNAs, the expression of miR-130a was verified using qRT-PCR. The expression of MDR1 mRNA and P-glycoprotein (P-gp) after cellular transfection was examined using qRT-PCR and western blotting, respectively. Cisplatin sensitivity was detected by the MTT assay. We indentified 35 downregulated and 54 upregulated miRNAs in SKOV3/CIS compared to those in SKOV3. We found that miR-130a was upregulated in SKOV3/CIS compared to the parental SKOV3 cells, and PTEN was predicted to be the potential target of miR-130a. Moreover, downregulation of miR-130a could inhibit MDR1 mRNA and P-gp expression and overcome the cisplatin resistance in SKOV3/CIS cells, which indicated that miR-130a may be associated with MDR1/P-gp-mediated drug resistance and plays the role of an intermediate in drug-resistance pathways of PI3K/Akt/PTEN/mTOR and ABC superfamily drug transporters in SKOV3/CIS cells. This study provides important information for the development of targeted gene therapy for reversing cisplatin resistance in ovarian cancer.
机译:microRNA(miRNA)是短的非编码RNA分子,参与各种生物过程的调控。耐药性已经成为卵巢癌成功化疗的主要障碍。这项研究的目的是调查在顺铂耐药卵巢癌细胞中的microRNA表达谱以及miR-130a在调节耐药性中的作用。通过miRNA微阵列评估了SKOV3和SKOV3 / CIS细胞之间差异表达的miRNA。 miRNA的靶标预测是在PicTar或TargetScan的帮助下确定的。在这些miRNA中,使用qRT-PCR验证了miR-130a的表达。细胞转染后,分别使用qRT-PCR和Western blotting检测MDR1 mRNA和P-糖蛋白(P-gp)的表达。通过MTT测定法检测顺铂敏感性。与SKOV3中的miRNA相比,我们确定了SKOV3 / CIS中的35个下调的miRNA和54个上调的miRNA。我们发现与亲代SKOV3细胞相比,miR-130a在SKOV3 / CIS中被上调,并且PTEN被预测为miR-130a的潜在靶标。此外,miR-130a的下调可能抑制MDR1 mRNA和P-gp的表达并克服SKOV3 / CIS细胞中的顺铂耐药性,这表明miR-130a可能与MDR1 / P-gp介导的耐药性有关并发挥作用在SKOV3 / CIS细胞中PI3K / Akt / PTEN / mTOR和ABC超家族药物转运蛋白的耐药途径中的中间体这项研究为开发靶向基因治疗逆转卵巢癌顺铂耐药性提供了重要信息。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号